|
1
|
Pharoah PD, Dunning AM, Ponder BA and
Easton DF: Association studies for finding cancer-susceptibility
genetic variants. Nat Rev Cancer. 4:850–860. 2004.
|
|
2
|
Lu KP: Pinning down cell signaling, cancer
and Alzheimer’s disease. Trends Biochem Sci. 29:200–209. 2004.
|
|
3
|
Lu KP: Prolyl isomerase Pin1 as a
molecular target for cancer diagnostics and therapeutics. Cancer
Cell. 4:175–180. 2003.
|
|
4
|
Ranganathan R, Lu KP, Hunter T and Noel
JP: Structural and functional analysis of the mitotic rotamase Pin1
suggests substrate recognition is phosphorylation dependent. Cell.
89:875–886. 1997.
|
|
5
|
Lu KP, Hanes SD and Hunter T: A human
peptidyl-prolyl isomerase essential for regulation of mitosis.
Nature. 380:544–547. 1996.
|
|
6
|
Lu KP and Zhou XZ: The prolyl isomerase
Pin1: a pivotal new twist in phosphorylation signalling and
disease. Nat Rev Mol Cell Biol. 8:904–916. 2007.
|
|
7
|
Miyashita H, Mori S, Motegi K, Fukumoto M
and Uchida T: Pin1 is overexpressed in oral squamous cell carcinoma
and its levels correlate with cyclin D1 overexpression. Oncol Rep.
10:455–461. 2003.
|
|
8
|
Wulf GM, Ryo A, Wulf GG, et al: Pin1 is
overexpressed in breast cancer and cooperates with Ras signaling in
increasing the transcriptional activity of c-Jun towards cyclin D1.
EMBO J. 20:3459–3472. 2001.
|
|
9
|
Zhou XZ, Kops O, Werner A, et al:
Pin1-dependent prolyl isomerization regulates dephosphorylation of
Cdc25C and tau proteins. Mol Cell. 6:873–883. 2000.
|
|
10
|
Arnold HK, Zhang X, Daniel CJ, et al: The
Axin1 scaffold protein promotes formation of a degradation complex
for c-Myc. EMBO J. 28:500–512. 2009.
|
|
11
|
Ryo A, Nakamura M, Wulf G, Liou YC and Lu
KP: Pin1 regulates turnover and subcellular localization of
beta-catenin by inhibiting its interaction with APC. Nat Cell Biol.
3:793–801. 2001.
|
|
12
|
Pathan N, Aime-Sempe C, Kitada S, et al:
Microtubule-targeting drugs induce bcl-2 phosphorylation and
association with Pin1. Neoplasia. 3:550–559. 2001.
|
|
13
|
Ryo A, Liou YC, Lu KP and Wulf G: Prolyl
isomerase Pin1: a catalyst for oncogenesis and a potential
therapeutic target in cancer. J Cell Sci. 116:773–783. 2003.
|
|
14
|
Ayala G, Wang D, Wulf G, et al: The prolyl
isomerase Pin1 is a novel prognostic marker in human prostate
cancer. Cancer Res. 63:6244–6251. 2003.
|
|
15
|
Ryo A, Liou YC, Wulf G, et al: Pin1 is an
E2F target gene essential for Neu/Ras-induced transformation of
mammary epithelial cells. Mol Cell Biol. 22:5281–5295. 2002.
|
|
16
|
Ryo A, Uemura H, Ishiguro H, et al: Stable
suppression of tumorigenicity by Pin1-targeted RNA interference in
prostate cancer. Clin Cancer Res. 11:7523–7531. 2005.
|
|
17
|
Lu J, Yang L, Zhao H, et al: The
polymorphism and haplotypes of PIN1 gene are associated with
the risk of lung cancer in Southern and Eastern Chinese
populations. Hum Mutat. 32:1299–1308. 2011.
|
|
18
|
Segat L, Pontillo A, Annoni G, et al: Pin1
promoter polymorphisms are associated with Alzheimer’s disease.
Neurobiol Aging. 28:69–74. 2007.
|
|
19
|
Segat L, Milanese M and Crovella S: Pin1
promoter polymorphisms in hepatocellular carcinoma patients.
Gastroenterology. 132:2618–2619. 2007.
|
|
20
|
Han CH, Lu J, Wei Q, et al: The functional
promoter polymorphism (−842G>C) in the Pin1 gene is associated
with decreased risk of breast cancer in non-Hispanic white women 55
years and younger. Breast Cancer Res Treat. 122:243–249. 2010.
|
|
21
|
Naidu R, Har YC and Taib NA: Analysis of
peptidyl-propyl-cis/trans isomerase 1 (PIN1) gene −842 (G>C) and
−667 (T>C) polymorphic variants in relation to breast cancer
risk and clinico-pathological parameters. Scand J Clin Lab Invest.
71:500–506. 2011.
|
|
22
|
Lu J, Hu Z, Wei S, et al: A novel
functional variant (−842G>C) in the PIN1 promoter contributes to
decreased risk of squamous cell carcinoma of the head and neck by
diminishing the promoter activity. Carcinogenesis. 30:1717–1721.
2009.
|
|
23
|
Lu Y, Huang GL, Pu XX, et al: Association
between PIN1 promoter polymorphisms and risk of nasopharyngeal
carcinoma. Mol Biol Rep. 40:3777–3782. 2013.
|
|
24
|
You Y, Deng J, Zheng J, et al: Functional
polymorphisms in PIN1 promoter and esophageal carcinoma
susceptibility in Chinese population. Mol Biol Rep. 40:829–838.
2013.
|
|
25
|
Handoll HH: Systematic reviews on
rehabilitation interventions. Arch Phys Med Rehabil.
87:8752006.
|
|
26
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.
|
|
27
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
|
|
28
|
Whitehead A and Whitehead J: A general
parametric approach to the meta-analysis of randomized clinical
trials. Stat Med. 10:1665–1677. 1991.
|
|
29
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997.
|
|
30
|
Bao L, Kimzey A, Sauter G, et al:
Prevalent overexpression of prolyl isomerase Pin1 in human cancers.
Am J Pathol. 164:1727–1737. 2004.
|
|
31
|
Arboleda MJ, Lyons JF, Kabbinavar FF, et
al: Overexpression of AKT2/protein kinase Bbeta leads to
up-regulation of beta1 integrins, increased invasion, and
metastasis of human breast and ovarian cancer cells. Cancer Res.
63:196–206. 2003.
|
|
32
|
Fukuchi M, Fukai Y, Kimura H, et al:
Prolyl isomerase Pin1 expression predicts prognosis in patients
with esophageal squamous cell carcinoma and correlates with
cyclinD1 expression. Int J Oncol. 29:329–334. 2006.
|
